eprosartan + hydrochlorothiazide + moxonidine

**Eprosartan + hydrochlorothiazide + moxonidine** is an oral triple-combination therapy used in the management of hypertension, particularly in patients with concomitant type 2 diabetes who require multiple antihypertensive agents for optimal blood pressure control. - **Eprosartan** is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and lower blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that reduces blood pressure by promoting sodium and water excretion, thereby decreasing blood volume. - **Moxonidine** is a centrally acting imidazoline receptor agonist that reduces sympathetic nervous system activity, also resulting in lowered blood pressure. This combination targets multiple mechanisms contributing to hypertension and is particularly studied for patients who have not reached blood pressure targets on single or dual therapy, offering synergistic blood pressure reduction and potentially improved metabolic and renal outcomes[1][3].